Gilead Sciences Inc (GILD)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ
Market Cap: $208.48B
Last updated: Nov 17, 2026 at 11:06 AM ET
Gilead Sciences Inc (GILD) Financials: Revenue, Profit and Cash Flow
Gilead Sciences reported revenue of $29.44B for the fiscal year ended Dec 31, 2025, up 2.4% from the year before. That year, net income was $8.51B with a net margin of 28.9%, operating cash flow was $10.02B and free cash flow was $9.46B. The quarter ended Sep 30, 2026 had revenue of $8.30B and net income of $2.43B.
Revenue and Margins
The operating margin was 34.0% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue fell from $30.39B, a compound annual decline of 0.4%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $29.44B | +2.4% | 78.8% | 34.0% | 28.9% |
| Dec 2024 | $28.75B | +6.0% | 78.3% | 5.8% | 1.7% |
| Dec 2023 | $27.12B | -0.6% | 76.0% | 28.0% | 20.7% |
| Dec 2022 | $27.28B | -0.1% | 79.3% | 26.9% | 16.7% |
| Dec 2021 | $27.30B | +10.6% | 75.8% | 36.3% | 22.7% |
| Dec 2020 | $24.69B | +10.0% | 81.5% | 16.5% | 0.4% |
| Dec 2019 | $22.45B | +1.5% | 79.2% | 19.1% | 23.9% |
| Dec 2018 | $22.13B | -15.2% | 78.1% | 37.1% | 24.7% |
| Dec 2017 | $26.11B | -14.1% | 83.3% | 54.1% | 17.8% |
| Dec 2016 | $30.39B | N/A | 86.0% | 58.0% | 44.4% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 1672.9% from the year before. In the quarter ended Sep 2026, net income fell 20.3% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29.44B | $28.75B | $27.12B | $27.28B | $27.30B | $24.69B | $22.45B | $22.13B | $26.11B | $30.39B |
| Cost of revenue | $6.23B | $6.25B | $6.50B | $5.66B | $6.60B | $4.57B | $4.67B | $4.85B | $4.37B | $4.26B |
| Gross profit | $23.21B | $22.50B | $20.62B | $21.62B | $20.70B | $20.12B | $17.77B | $17.27B | $21.74B | $26.13B |
| Research and development | $6.82B | $10.57B | $6.87B | $5.92B | $5.54B | $10.89B | $9.11B | $5.02B | $3.73B | $5.10B |
| Operating income | $10.02B | $1.66B | $7.61B | $7.33B | $9.92B | $4.07B | $4.29B | $8.20B | $14.12B | $17.63B |
| Net income | $8.51B | $480.00M | $5.61B | $4.57B | $6.20B | $89.00M | $5.36B | $5.46B | $4.64B | $13.49B |
| EBITDA | $13.58B | $4.43B | $10.50B | $8.85B | $11.33B | $4.13B | $7.56B | $10.30B | $15.93B | $19.22B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.30B | $7.80B | $6.96B | $7.92B | $7.77B | $7.08B | $6.67B | $7.57B | $7.54B | $6.95B | $6.69B | $7.11B |
| Gross profit | $6.73B | $6.22B | $5.51B | $6.30B | $6.20B | $5.58B | $5.13B | $5.99B | $5.97B | $5.41B | $5.13B | $5.02B |
| Operating income | $3.46B | -$10.39B | $2.59B | $1.98B | $3.33B | $2.47B | $2.24B | $2.45B | $888.00M | $2.64B | -$4.32B | $1.61B |
| Net income | $2.43B | -$10.50B | $2.02B | $2.18B | $3.05B | $1.96B | $1.31B | $1.78B | $1.25B | $1.61B | -$4.17B | $1.42B |
Balance Sheet
As of Dec 2025, total debt of $24.94B exceeded cash and equivalents by $17.37B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $59.02B | $58.99B | $62.13B | $63.17B | $67.95B | $68.41B | $61.63B | $63.67B | $70.28B | $56.98B |
| Current assets | $18.34B | $19.17B | $16.09B | $14.44B | $14.77B | $16.00B | $30.30B | $35.84B | $31.82B | $19.59B |
| Cash and equivalents | $7.56B | $9.99B | $6.08B | $5.41B | $5.34B | $6.00B | $11.63B | $17.94B | $7.59B | $8.23B |
| Total liabilities | $36.41B | $39.75B | $39.38B | $41.96B | $46.89B | $50.19B | $38.98B | $42.14B | $49.78B | $37.61B |
| Short-term debt | $2.81B | $1.81B | $1.80B | $2.27B | $1.52B | $2.76B | $2.50B | $2.75B | $2.75B | $0 |
| Long-term debt | $22.13B | $24.90B | $23.19B | $22.96B | $25.18B | $28.64B | $22.09B | $24.57B | $30.80B | $26.35B |
| Shareholder equity | $22.70B | $19.33B | $22.83B | $21.24B | $21.07B | $18.20B | $22.52B | $21.39B | $20.44B | $18.89B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $51.41B | $49.36B | $56.28B | $59.02B | $58.53B | $55.72B | $56.43B | $58.99B | $54.52B | $53.58B | $56.29B | $62.13B |
| Total liabilities | $38.45B | $37.62B | $32.85B | $36.41B | $37.08B | $36.13B | $37.35B | $39.75B | $36.13B | $35.38B | $38.84B | $39.38B |
| Cash and equivalents | $6.44B | $3.18B | $7.63B | $7.56B | $7.33B | $5.14B | $7.93B | $9.99B | $5.04B | $2.77B | $4.72B | $6.08B |
| Shareholder equity | $13.04B | $11.83B | $23.52B | $22.70B | $21.54B | $19.67B | $19.16B | $19.33B | $18.48B | $18.28B | $17.54B | $22.83B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 94.4% of operating cash flow. Dividends and share repurchases together came to 62.6% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $10.02B | $10.83B | $8.01B | $9.07B | $11.38B | $8.17B | $9.14B | $8.40B | $11.90B | $17.05B |
| Capital expenditures | $563.00M | $523.00M | $585.00M | $728.00M | $579.00M | $650.00M | $825.00M | $924.00M | $590.00M | $748.00M |
| Free cash flow | $9.46B | $10.30B | $7.42B | $8.34B | $10.80B | $7.52B | $8.32B | $7.48B | $11.31B | $16.30B |
| Dividends paid | $4.00B | $3.92B | $3.81B | $3.71B | $3.60B | $3.45B | $3.22B | $2.97B | $2.73B | $2.46B |
| Share repurchases | $1.92B | $1.15B | $1.00B | $1.40B | $546.00M | $1.58B | $1.75B | $2.90B | $954.00M | $11.00B |
| Investing cash flow | -$4.79B | -$3.45B | -$2.27B | -$2.47B | -$3.13B | -$14.62B | -$7.82B | $14.36B | -$16.07B | -$11.98B |
| Financing cash flow | -$7.75B | -$3.43B | -$5.13B | -$6.47B | -$8.88B | $770.00M | -$7.63B | -$12.32B | $3.39B | -$9.72B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $5.04B | $3.57B | $2.54B | $3.33B | $4.11B | $827.00M | $1.76B | $2.98B | $4.31B | $1.32B | $2.22B | $2.17B |
| Capital expenditures | $237.00M | $140.00M | $117.00M | $205.00M | $147.00M | $107.00M | $104.00M | $147.00M | $141.00M | $130.00M | $105.00M | $215.00M |
| Free cash flow | $4.80B | $3.43B | $2.43B | $3.12B | $3.96B | $720.00M | $1.65B | $2.83B | $4.17B | $1.20B | $2.11B | $1.95B |
Frequently Asked Questions About GILD
What is Gilead Sciences' annual revenue?
Gilead Sciences reported revenue of $29.44B for the fiscal year ended Dec 31, 2025.
How fast is Gilead Sciences' revenue growing?
Revenue was up 2.4% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 2.6%.
Is Gilead Sciences profitable?
Yes. Gilead Sciences reported net income of $8.51B for the fiscal year ended Dec 31, 2025, with a net margin of 28.9%.
How much free cash flow does GILD generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $10.02B minus capital expenditures of $563.00M produced free cash flow of $9.46B.
How much debt does Gilead Sciences have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $22.13B, short-term debt of $2.81B and cash and equivalents of $7.56B.
GILD pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts